LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Meridian Demonstrates State-of-the-Art Urea Breath Test System at AACC 2022

By LabMedica International staff writers
Posted on 27 Jul 2022
Print article
Image: BreathID platform offers a cost-effective clinical diagnostic solution (Photo courtesy of Meridian)
Image: BreathID platform offers a cost-effective clinical diagnostic solution (Photo courtesy of Meridian)

Meridian Bioscience Inc. (Cincinnati, OH, USA) is attending the 73rd AACC Annual Scientific Meeting & Clinical Lab Expo where the company will exhibit its state-of-the-art urea breath test system alongside its advanced fluorescent immunoassay and molecular platforms.

At AACC 2022, Meridian will display its state-of-the-art BreathID Hp Lab urea breath test system for H. pylori detection that intuitively combines market-leading diagnostic accuracy with efficient automation and fast batch-test analysis for maximizing large lab testing throughput. The system’s built-in automated monitoring manages batch analysis, moving from test sample to test sample while noting any sample errors for post-batch handling. The BreathID platform can be used in conjunction with other Meridian H. pylori platforms for a total testing solution across the health system.

Meridian is also exhibiting the Curian fluorescent immunoassay platform focused on gastrointestinal testing that is packaged in a small footprint to improve hospital operational efficiencies. Curian provides healthcare systems a rapid fluorescent immunoassay diagnostic solution with a standardized, simplified workflow that eliminates subjectivity. Laboratories can eliminate workflow burdens and achieve optimal efficiency while delivering top-of-the-line patient care.

Also on display at Meridian’s booth will be the company’s Revogene flexible molecular platform capable of single analyte and multiplex testing that is packaged in a small footprint, and can help standardize testing throughout the health system. Revogene is a fully automated molecular platform that features single and multiplex testing capabilities with minimal hands-on time. The flexible, scalable platform comes with a broad test menu for the detection of hospital inquired infections, gastrointestinal, respiratory, and neonatal diseases.
 

Related Links:
Meridian Bioscience Inc. 

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.